Company · DSNKY
Daiichi Sankyo
Last checked: Nov 20, 2026Source: Drugs@FDA, ClinicalTrials.gov
NDAs and BLAs
7
6 still marketed
Novel approvals
6
Approvals since 2021
21
Originals and new uses
Phase 3 trials
97
Registered, any status
Trials by phase
All registered drug and biologic trials with this lead sponsor, any status. A public view of the pipeline.
Recent approvals
Originals and efficacy supplements, newest first.
- Datroway new use Priority reviewMay 22, 2026
- Enhertu new use Breakthrough therapyPriority reviewOrphanMay 15, 2026
- Enhertu new use OrphanMay 15, 2026
- Enhertu new use OrphanApr 27, 2026
- Enhertu new use Breakthrough therapyPriority reviewOrphanDec 15, 2025
- Datroway approved NovelBreakthrough therapyAccelerated approvalPriority reviewJun 23, 2025
- Enhertu new use Breakthrough therapyPriority reviewOrphanJan 27, 2025
- Datroway approved NovelJan 17, 2025
- Enhertu new use Breakthrough therapyPriority reviewOrphanApr 5, 2024
- Enhertu new use OrphanFeb 15, 2024
Drugs in development (11)
Investigational drugs, not yet FDA-approved, in this company's active or recent Phase 2 and 3 trials. Phase 3 first.
- I-DXdDS-7300a, MK-2400Phase 317 trials
Merck & Co. · Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Esophageal Squamous Cell Carcinoma
- R-DXdDS 6000a, MK-5909Phase 310 trials
Merck & Co. · Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cancer
- OlomorasibLY3537982Phase 36 trials
Eli Lilly · Carcinoma, Non-Small-Cell Lung, Colorectal Neoplasms, Neoplasm Metastasis
- AmrubicinJapan onlyPhase 34 trials
Gilead Sciences · Small Cell Lung Cancer, Extensive Stage Small Cell Lung Cancer (ES-SCLC), Small Cell Lung Cancer (SCLC)
- SafusidenibDS-1001b, AB-218Phase 34 trials
Nuvation Bio Inc. · Oligodendroglioma, Glioma, IDH1-mutant Glioma
- valemetostat tosylateDS-3201bPhase 23 trials
Daiichi Sankyo · Non-small Cell Lung Cancer, Lung Cancer, Relapsed/Refractory Peripheral T-Cell Lymphoma
- DS-3939aPhase 22 trials
Daiichi Sankyo · Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- DS-1103aPhase 21 trial
Daiichi Sankyo · Solid Tumor, Locally Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small Cell Lung Cancer
- DS-7011aPhase 21 trial
Daiichi Sankyo · Systemic Lupus Erythematosus
- DS3790aPhase 21 trial
Daiichi Sankyo · Hematological Malignancies, B-cell Non-Hodgkin Lymphoma
- RenadirsenDS-5141bPhase 21 trial
Daiichi Sankyo · Duchenne Muscular Dystrophy
Recruiting Phase 3 trials
Largest first.
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06161025 · 860 participants (planned) · Start Feb 27, 2024 · Primary completion Feb 29, 2028
Drug: R-DXd; Paclitaxel and 2 more · For: Solid Cancer
Sites: Anchorage, Alaska; New Haven, Connecticut; Coral Gables, Florida · 167 sites in all
- Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06731478 · 726 participants (planned) · Start Feb 27, 2025 · Primary completion Jun 1, 2028
Drug: Trastuzumab Deruxtecan; pembrolizumab and 2 more · For: Gastric Cancer; Gastroesophageal Junction Cancer
Sites: New Haven, Connecticut; Skokie, Illinois; Kansas City, Kansas · 250 sites in all
- A Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer in Adjuvant SettingPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07022483 · 710 participants (planned) · Start Sep 30, 2025 · Primary completion Feb 26, 2030
Drug: Trastuzumab Deruxtecan; Chemotherapy · For: Endometrial Cancer
Sites: Fort Lauderdale, Florida; Miami, Florida; Miami Beach, Florida · 86 sites in all
- Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06899126 · 686 participants (planned) · Start Oct 24, 2025 · Primary completion Apr 24, 2030
Drug: Trastuzumab Deruxtecan; pembrolizumab and 2 more · For: Non-small Cell Lung Cancer
Sites: Anchorage, Alaska; Fountain Valley, California; Los Angeles, California · 247 sites in all
- Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial CarcinomaPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07129993 · 630 participants (planned) · Start Sep 26, 2025 · Primary completion Jun 1, 2029
Drug: Dato-DXd; Carboplatin and 2 more · For: Urothelial Cancer; Bladder Cancer
Sites: Fullerton, California; Glendale, California; La Jolla, California · 100 sites in all
- Study of Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer (DESTINY-Ovarian01)Pivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06819007 · 582 participants (planned) · Start Mar 19, 2025 · Primary completion Nov 1, 2028
Drug: Trastuzumab Deruxtecan; Bevacizumab · For: Ovarian Cancer
Sites: Burbank, California; La Jolla, California; Palo Alto, California · 232 sites in all
- A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06203210 · 540 participants (planned) · Start May 21, 2024 · Primary completion Jan 30, 2028
Drug: Ifinatamab deruxtecan; Topotecan and 2 more · For: Small Cell Lung Cancer
Sites: Springdale, Arkansas; Fullerton, California; Los Angeles, California · 229 sites in all
- A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01)Pivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT06644781 · 510 participants (planned) · Start Mar 27, 2025 · Primary completion Jun 1, 2028
Drug: Ifinatamab deruxtecan; Docetaxel and 2 more · For: Esophageal Squamous Cell Carcinoma
Sites: Phoenix, Arizona; Fullerton, California; Los Angeles, California · 168 sites in all
- Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast CancerPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT05950945 · 250 participants (planned) · Start Dec 30, 2023 · Primary completion Oct 1, 2027
Drug: Trastuzumab Deruxtecan · For: Breast Cancer
Sites: Miami Beach, Florida; Tampa, Florida; Boston, Massachusetts · 88 sites in all
- T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXdPivotal-lookingRecruiting
Daiichi SankyoDaiichi Sankyo (DSNKY)
NCT07683754 · 200 participants (planned) · Start Nov 4, 2026 · Primary completion Jul 4, 2030
Drug: Trastuzumab deruxtecan; Trastuzumab and 3 more · For: Advanced Breast Cancer; Metastatic Breast Cancer; HER2 Positive and 1 more
Sites: Columbia, Maryland; Las Vegas, Nevada; Nashville, Tennessee · 6 sites in all
Marketed drugs (6)
Newest FDA action first.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.